Corcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is Not
Corcept Therapeutics is upgraded to Buy after a patent loss and FDA setback, with focus shifting to relacorilant in oncology. Despite Korlym's imminent generic erosion, CORT's $524M liquidity and cost controls provide a six-quarter runway to finance relacorilant's commercialization. Exceptional Phase 3 ROSELLA data in platinum-resistant ovarian cancer position relacorilant for "standard-of-care" status and potentially $3.38B in peak sales.
CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study
Corcept jumps after relacorilant plus nab-paclitaxel hits overall survival endpoint in phase III ROSELLA study in platinum-resistant ovarian cancer.
One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit
Corcept Therapeutics (NASDAQ: CORT) and Amicus Therapeutics (NASDAQ: FOLD) delivered Q3 2025 results highlighting two rare disease biotechs at opposite ends of the profitability spectrum.
Corcept (CORT) Surges 9.8%: Is This an Indication of Further Gains?
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug
Corcept Therapeutics (CORT) leverages Korlym's commercial success in hypercortisolism, generating $559.3M in nine-month 2025 revenue and $19M Q3 net income. Despite positive Phase 3 data, the FDA unexpectedly rejected CORT's NDA for Relacorilant, citing insufficient benefit-risk evidence. Korlym's ongoing revenues provide a valuation floor and financial support for further Relacorilant trials.
Corcept (CORT) Up 9.2% Since Last Earnings Report: Can It Continue?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Will Korlym Continue to Drive Corcept's Top Line in 2026?
CORT leans on rising Korlym sales while awaiting key relacorilant FDA decisions that could broaden its growth path in 2026.
Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down
CORT's third-quarter earnings and sales miss estimate. The company cuts guidance despite a 14% year-over-year rise in revenues.
Corcept Therapeutics Incorporated (CORT) Q3 2025 Earnings Call Transcript
Corcept Therapeutics Incorporated ( CORT ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Atabak Mokari - CFO & Treasurer Gary Robb - Chief Business Officer & Secretary Sean Maduck - President of Endocrinology Joseph K. Belanoff - Co-Founder, President, CEO & Director William Guyer - Chief Development Officer Conference Call Participants Edward Nash - Canaccord Genuity Corp., Research Division David Amsellem - Piper Sandler & Co., Research Division Asim Rana - Truist Securities, Inc., Research Division Swayampakula Ramakanth - H.C.
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Miss Estimates
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.16 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.41 per share a year ago.
Analysts Estimate Corcept Therapeutics (CORT) to Report a Decline in Earnings: What to Look Out for
Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CORT Files MAA for Relacorilant in Platinum-Resistant Ovarian Cancer
Corcept files a marketing application with the EMA for relacorilant in platinum-resistant ovarian cancer after studies show survival gains.
